Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Diurnal, Hugel, Knight, Lyell, Revive.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beigene, Biontech, Evonik, Gennisium, Immune-Onc, Merck, Phathom, Pierre Fabre, Ridgeback, Teva.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allogene, Clarity, Icosavax, Mersana, Octapharma, Oravax, Prolynx.
Aim Vaccine Co. Ltd. priced an IPO on the Hong Kong Stock Exchange, raising HK$70.01 million (US$9 million) to fund work on its late-stage vaccine pipeline. Its shares increased only 3.09% on debut Oct. 6 but closed the week at HK$24.80, up 54% over its listing price of HK$16.16.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ABVC, Annovis, Clarametyx, Crinetics, Eiger, Eli Lilly, Entera, Evofem, Humanetics, Immutep, Kiromic, Nova Mentis, Takeda, Transcenta.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biomarin, Nektar, Pharmacyte, Puretech, Teva.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Aridis, Connect, Kalvista, Kubota, Paradigm, Pfizer, Saol, Synairgen.
Although U.S. President Joe Biden suggested in September that the pandemic is over, health officials insist there is still much to do in preparation for an endemic stage of the SARS-CoV-2 virus. The number of weekly COVID-19 confirmed cases both globally and in the U.S. is similar with each of the last two years, but deaths from the virus are at some of the lowest levels since the pandemic began. Still, the virus will continue to evolve and circulate, and the biopharma industry will need to develop new booster vaccines, antivirals and monoclonal antibodies, among other candidates, to prepare for upcoming battles.
Three months after agreeing to an intellectual property waiver for COVID-19 vaccines, World Trade Organization (WTO) members are discussing expanding it to therapies, diagnostics and devices used in preventing, diagnosing and treating COVID-19 infections.
RSS
